StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

APTO has been the subject of several other research reports. Canaccord Genuity Group dropped their target price on Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research report on Thursday, May 16th. HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Aptose Biosciences in a report on Friday, June 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Aptose Biosciences has a consensus rating of Moderate Buy and a consensus target price of $9.00.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.36 on Tuesday. The firm has a market capitalization of $6.54 million, a PE ratio of -0.06 and a beta of 1.25. The stock’s fifty day moving average is $0.52 and its 200 day moving average is $0.99. Aptose Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $3.54.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.15. Equities analysts forecast that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.